利福昔明和肝硬化患者的生存：一个未实现的临床承诺

IF 33 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-08-20 DOI:10.1016/j.jhep.2025.08.011

Lorenzo Ridola, Oliviero Riggio

引用次数: 0

摘要

章节片段作者的贡献slorenzo Ridola和Oliviero Riggio：概念化和手稿写作，重要知识内容的关键修改，最终批准财务支持无竞争利益声明无请参阅随附的ICMJE披露表格了解更多细节。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise

Section snippets

Authors' contributions

Lorenzo Ridola and Oliviero Riggio: conceptualization and manuscript writing, critical revision for important intellectual content, final approval

Financial support

None

Declaration of Competing Interest

NonePlease refer to the accompanying ICMJE disclosure forms for further details.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.